4-Tert-butyl-5-propan-2-yl-1,2-oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Tert-butyl-5-propan-2-yl-1,2-oxazole
• 英文别名: 4-tert-butyl-5-propan-2-yl-1,2-oxazole
• 化学式: C₁₀H₁₇NO
• 分子量: 167.25
• InChiKey: LROKOATULYHNQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。
• Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11192900B2

  公开（公告）日：2021-12-07

  Novel bromodomain and extraterminal domain (BET) inhibitors contanining substituted 2-pyridones and therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

  本研究提供了含有取代的 2-吡啶酮的新型溴结构域和外结构域（BET）抑制剂，以及使用这些新型 BET 抑制剂治疗病症和疾病的方法。
• TLR7/8 ANTAGONISTS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20180037570A1

  公开（公告）日：2018-02-08

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
• HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
  申请人：NUVATION BIO INC.

  公开号：US20200140459A1

  公开（公告）日：2020-05-07

  Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
• SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME
  申请人：Guangzhou Maxinovel Pharmaceuticals Co., Ltd.

  公开号：US20220168268A1

  公开（公告）日：2022-06-02

  A small molecule inhibitor of PD-1/PD-L1, a pharmaceutical composition thereof with a PD-L1 antibody, and an application of the same. The small molecule inhibitor of PD-1/PD-L1 is aromatic ethylene or aromatic ethylene derivative represented by general formula (I) and can be used to treat cancer.